EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) for Treatment of Fibromyalgia: A Comprehensive Clinical Review

Aila Malik, Zoe Brown, Alexa Ryder, Vanshika Balayan, Lauren Jameson, Peter Vu, Rana Al-Jumah, Jamal Hasoon

Psychopharmacology Bulletin · 2025

DOI: 10.64719/pb.4519 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Psychopharmacology Bulletin, 2025. Verfasst von Aila Malik und 7 weiteren Autor:innen. Beteiligte Einrichtung: Malik, University of Texas Health Science Center at Houston, Department of Physical Medicine and Rehabilitation, Houston, TX, USA. Hauptthemen laut MEDLINE: Fibromyalgia, Serotonin and Noradrenaline Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibromyalgia is a complex clinical entity characterized by a broad range of symptoms including chronic widespread musculoskeletal pain, profound fatigue, impaired cognition, and mood disturbances. Current understanding of disease pathogenesis assumes neurotransmitter dysregulation and central pain sensitization play a key role resulting in heightened pain sensitivity. Genetic predisposition as well as alterations in endocrine and immune function have been implicated. Accurate diagnosis requires a comprehensive evaluation, and a personalized treatment approach is needed to address the biopsychosocial components of the disease process. Among pharmacologic treatment options, serotonin norepinephrine reuptake inhibitors (SNRIs) have demonstrated analgesic effects in addition to mood stabilizing properties. Currently, duloxetine and milnacipran are approved by the Food and Drug Administration although other agents in this drug class including venlafaxine and desvenlafaxine have been studied in the management of fibromyalgia. In addition, selective norepinephrine reuptake inhibitors, esreboxetine and reboxetine, as well as tramadol, a weak opioid mu-receptor agonist with SNRI activity have shown potential utility. Although some studies have demonstrated SNRIs to be effective and well tolerated in patients with fibromyalgia, individual response may vary. There remains a continued need for large scale clinical trials to establish the safety and clinical effectiveness of these agents in this patient population. Further information is needed to optimize patient selection and dosing regimens as well as elucidate the clinical factors associated with poor response. Moreover, pharmacologic agents may be combined with lifestyle changes and non-drug-based treatments to address the complex interactions of biological and psychosocial factors that facilitate disease development and persistence of symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FibromyalgiaSerotonin and Noradrenaline Reuptake InhibitorsSelective Serotonin Reuptake InhibitorsHumansDuloxetine Hydrochloride

Stichwörter der Autor:innen

SNRIchronic painfibromyalgiamusculoskeletal painneuropathic painselective norepinephrine reuptake inhibitor

Substanzen

Serotonin and Noradrenaline Reuptake InhibitorsSelective Serotonin Reuptake InhibitorsDuloxetine Hydrochloride

Autor:innen und Institutionen

  • Malik, University of Texas Health Science Center at Houston, Department of Physical Medicine and Rehabilitation, Houston, TX, USA.
  • Brown, University of Texas Health Science Center at Houston, Department of Anesthesiology, Critical Care, and Pain Medicine, Houston, TX, USA.
  • Ryder, University of Texas Health Science Center at Houston, Department of Physical Medicine and Rehabilitation, Houston, TX, USA.
  • Balayan, University of Texas Health Science Center at Houston, Department of Anesthesiology, Critical Care, and Pain Medicine, Houston, TX, USA.
  • Jameson, University of Texas Health Science Center at Houston, Department of Anesthesiology, Critical Care, and Pain Medicine, Houston, TX, USA.
  • Vu, University of Texas Health Science Center at Houston, Department of Physical Medicine and Rehabilitation, Houston, TX, USA.

Zitieren

APA

Malik, A., Brown, Z., Ryder, A., Balayan, V., Jameson, L., Vu, P., Al-Jumah, R., & Hasoon, J. (2025). Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) for Treatment of Fibromyalgia: A Comprehensive Clinical Review. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.4519

Vancouver

Malik A, Brown Z, Ryder A, Balayan V, Jameson L, Vu P, et al. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) for Treatment of Fibromyalgia: A Comprehensive Clinical Review. Psychopharmacology Bulletin. 2025. doi:10.64719/pb.4519

BibTeX
@article{Malik2025,
  author = {Malik, Aila and Brown, Zoe and Ryder, Alexa and Balayan, Vanshika and Jameson, Lauren and Vu, Peter and Al-Jumah, Rana and Hasoon, Jamal},
  title = {Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) for Treatment of Fibromyalgia: A Comprehensive Clinical Review},
  journal = {Psychopharmacology Bulletin},
  year = {2025},
  doi = {10.64719/pb.4519}
}
Kostenlos starten →